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Abstract
Epidemiological studies have identified increased colorectal cancer (CRC) risk with high red meat (HRM) intakes, whereas dietary fibre
intake appears to be protective. In the present study, we examined whether a HRM diet increased rectal O6-methyl-2-deoxyguanosine
(O6MeG) adduct levels in healthy human subjects, and whether butyrylated high-amylose maize starch (HAMSB) was protective.
A group of twenty-three individuals consumed 300 g/d of cooked red meat without (HRM diet) or with 40 g/d of HAMSB (HRM þ HAMSB
diet) over 4-week periods separated by a 4-week washout in a randomised cross-over design. Stool and rectal biopsy samples were col-
lected for biochemical, microbial and immunohistochemical analyses at baseline and at the end of each 4-week intervention period. The
HRM diet increased rectal O6MeG adducts relative to its baseline by 21 % (P,0·01), whereas the addition of HAMSB to the HRM diet pre-
vented this increase. Epithelial proliferation increased with both the HRM (P,0·001) and HRM þ HAMSB (P,0·05) diets when compared
with their respective baseline levels, but was lower following the HRM þ HAMSB diet compared with the HRM diet (P,0·05). Relative to
its baseline, the HRM þ HAMSB diet increased the excretion of SCFA by over 20 % (P,0·05) and increased the absolute abundances of the
Clostridium coccoides group (P,0·05), the Clostridium leptum group (P,0·05), Lactobacillus spp. (P,0·01), Parabacteroides distasonis
(P,0·001) and Ruminococcus bromii (P,0·05), but lowered Ruminococcus torques (P,0·05) and the proportions of Ruminococcus
gnavus, Ruminococcus torques and Escherichia coli (P,0·01). HRM consumption could increase the risk of CRC through increased
formation of colorectal epithelial O6MeG adducts. HAMSB consumption prevented red meat-induced adduct formation, which may be
associated with increased stool SCFA levels and/or changes in the microbiota composition.
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Colorectal cancer (CRC) is one of the most frequently diag-
nosed malignancies worldwide, accounting for 10 % of all
cancers and for approximately 20 % of all cancer-related
deaths in developed countries(1). Although there is a genetic
component in CRC development, diet and other lifestyle
factors are estimated to explain as much as 30–50 % of the
global incidence of the disease(2). According to the recent
report from the World Cancer Research Fund and American
Institute for Cancer Research (WCRF/AICR)(2,3), there is
convincing evidence that intake of red and processed meat
increases the risk of CRC, whereas intake of dietary fibre is
protective(4).
A variety of mechanisms have been proposed to link red
and processed meat consumption and the risk of CRC(5).
For red meat, in particular, it has been suggested that its
high content of haem Fe is a substantial contributor(6). Red
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meat undergoes fermentation in the colon that might alter the
microbiota composition and result in the production of poten-
tially genotoxic products that could play a role in oncogenesis.
These agents include N-nitroso compounds (NOC), a complex
mixture of nitrite-derived products formed either in processed
meat itself or endogenously in the human gut via bacterial
metabolism. NOC are alkylating agents that generate DNA
adducts in human colonocytes after high red meat consump-
tion(7). We have recently shown that the level of the
pro-mutagenic adduct O6-methyl-2-deoxyguanosine (O6MeG)
is increased in murine colonocytes after consuming a diet
high in red meat(8). O6MeG is a known toxic and mutagenic
base modification that, if unrepaired, can induce GC! AT
transition mutations (typically found in the K-ras gene in
human CRC)(9) and also recombination events or mutations
in the form of sister chromatid exchanges(10). More recently,
it has been suggested that high red meat consumption can
increase the expression of certain oncogenic microRNA(11).
Dietary fibre is a heterogeneous group of compounds, prin-
cipally indigestible carbohydrates of plant origin that include
NSP, starches that escape digestion in the small intestine
(resistant starches, RS) and oligosaccharides. One possible
mechanism for the reduction in the risk of CRC by dietary
fibre is the production of SCFA via fermentation by the
large-bowel microbiota(12). Of the major SCFA, butyrate is of
particular interest as it appears to be the preferred metabolic
substrate for colonocytes, and butyrate also promotes a
normal cellular phenotype. In vitro studies with CRC cell
lines have shown that butyrate induces apoptosis(13), reduces
cell proliferation and promotes differentiation(14). Animal
experiments have shown that butyrate may reduce colorectal
carcinogenesis by enhancing the apoptotic response to meth-
ylating carcinogens(15,16).
Increasing large-bowel butyrate supply has the potential to
improve colonic function and lower disease risk. RS is thought
to be particularly effective in this regard as its fermentation
generally favours butyrate production. Red meat and fibre
(including RS) are generally consumed together as com-
ponents of foods. Our animal studies have shown that dietary
RS is able to oppose colonocyte DNA strand breaks, telomere
shortening and pro-mutagenic DNA adduct formation in
rodents fed red meat(8,17,18). This protective effect correlated
most closely with large-bowel butyrate levels, supporting a
role for fermentation in risk modification. Acylated starches
(classified as RS4, chemically modified), in which the acyl
group is linked to the starch framework by an ester bond,
can deliver specific SCFA to the large bowel where bacterial
esterases release the SCFA. Ingestion of butyrylated high-
amylose maize starch increases colonic butyrate levels in ani-
mals(19) and humans(20). Accordingly, the present study was
carried out in healthy individuals to determine whether high
red meat consumption generated O6MeG adducts in rectal epi-
thelial cells, and whether concurrent consumption of high red
meat and butyrylated high-amylose maize starch opposed this
effect (primary aim). We also investigated the effects of these
diets on other indices of colonic health including rectal
proliferation, colonic fermentation products and microbiota
composition, as these might participate in the generation
of adducts.
Methods
Study design and participants
The present study was conducted as a double-blind, random-
ised cross-over trial consisting of two intervention periods of
4 weeks each, preceded by a 4-week run-in (baseline) and
separated by a 4-week (washout) period (Fig. 1). A group
of twenty-three healthy volunteers participated in the trial.
Exclusion criteria included evidence of active mucosal bowel
disease, intolerance to high-fibre foods or any perceived
contraindication to consumption of the test products. At enrol-
ment, all participants showed no active bowel disease. During
the entry (baseline) period, participants consumed their habit-
ual diets. For the interventions, they were allocated randomly
to a high red meat (HRM) diet or to a HRM diet supplemented
with 40 g/d of butyrylated high-amylose maize starch (HRM þ
HAMSB diet). During the HRM intervention, participants
consumed 300 g/d (raw weight) of cooked lean red meat
that was supplied frozen in 100 g packs of lean mince, beef
strips or lamb strips, with three packs to be consumed each
day. During the HRM þ HAMSB intervention, participants
Habitual diet/
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Fig. 1. Overview of the randomised cross-over intervention study design. HRM, high red meat; HAMSB, butyrylated high-amylose maize starch.
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were also required to consume a total of two pre-packed 20 g
sachets of HAMSB daily, one in the morning and one in the
evening by mixing the powder into 250 ml of reduced-fat
milk or orange juice. HAMSB was manufactured by Ingredion,
whereby 23 % of each glucopyranosyl unit in high-amylose
maize starch contained a butyrate molecule (degree of substi-
tution 0·23) and was of the same batch as the product used
previously(21). Participants on the HRM arm of the study
were asked to consume 250 ml of reduced-fat milk or
orange juice per d to match the HRM þ HAMSB intervention.
During the intervention periods, participants reduced their
intake of their habitual diet to accommodate the extra 300 g
red meat. Participants were instructed to maintain their usual
diet during the study but to avoid consuming high levels of
protein or fibre, or probiotic supplements, except those pre-
scribed for the study. Participants were also asked to avoid
consuming, or record the use of, any medication that could
interfere with bowel function (including antibiotics). Partici-
pants were monitored by a trial nurse (weekly) and dietitian
(at the end of each 4-week period) to ensure that diet and
intervention guidelines were followed, and weight was kept
stable. Details of medical history and medications, weight,
bowel health and symptoms, and adverse events were
collected by the trial nurse throughout the study. Composition
of the participants’ diets and compliance with the interven-
tions was assessed using weighed food diaries that were com-
pleted by the participants at the end of each 4-week dietary
period, 3 d before each clinic visit. Food diaries were entered
into FoodWorks Professional 7 Nutrition Calculation software
(Xyris Software) by a dietitian, to calculate energy and macro-
nutrient intake based on Australian food composition tables
and food manufacturers’ data. The present study was
approved by the Flinders Clinical Research Ethics Committee
(reference no. 155/09; Flinders Medical Centre, Bedford
Park, SA, Australia), and all volunteers gave written informed
consent. The present trial was registered in the Australian New
Zealand Clinical Trials Registry as ACTRN12609000306213
(http://www.anzctr.org.au).
Sample collection
Stool and rectal pinch biopsy samples were obtained at the
completion of the 4-week entry period (baseline) and at the
end of each intervention period. A complete faecal collection
was made by all participants for the last 48 h of each dietary
period, and the samples were stored in portable freezers
(2208C). At each visit to the Flinders Medical Centre clinic,
an experienced gastroenterologist collected four rectal
mucosal biopsies using alligator forceps through a 25 cm
rigid sigmoidoscope; this procedure was performed without
bowel preparation or prior dietary restriction. Biopsies were
formalin-fixed and dehydrated through gradient alcohol and
xylene before being embedded in paraffin wax.
Stool analyses
Faecal samples were thawed at 48C, pooled, homogenised,
and then subsampled for analysis. For the determination of
SCFA, weighed portions were diluted at 1:3 (w/w) with
deionised water containing 1·68 mmol heptanoic acid/l as an
internal standard (Sigma Chemical Co.), and processed for
SCFA analysis using GC as described previously(8). Total
SCFA concentration was calculated as the sum of acetic, pro-
pionic, butyric, isobutyric, caproic, isovaleric and valeric acid
concentrations. Total branched-chain fatty acids concentration
was calculated as the sum of isobutyric and isovaleric acid
concentrations. Phenol and p-cresols were measured in the
faeces by using vacuum microdistillation and HPLC(22).
Faecal NH3 concentration was measured by using the indo-
phenol blue method(23). Aqueous extracts of the faeces were
prepared by diluting 1 g faeces with 4 ml of distilled water,
homogenised and centrifuged (4500 rpm, 48C)(24), and total
apparent NOC were measured by chemical denitrosation
with HBr and chemiluminescence detection of the released
nitric oxide using a thermal energy analyser (TEA)(25,26). Con-
centrations were calculated by comparing the TEA response of
a faecal water sample with the response of an N-nitrosodipro-
pylamine standard (16·6mg/ml), and values were expressed as
total apparent NOC (ng/ml)(27).
Rectal biopsy analysis
The quantification of the O6MeG adduct load was performed
using an immunohistochemical detection method(8). The
immunohistochemical measurement of O6MeG adducts has
been previously used for many years mainly in different
animal species(8,28–32); however, this is the first time it has
been applied to human colonic crypts. The specificity of the
monoclonal antibody has been validated by RIA(33). In brief,
rectal biopsies were embedded in paraffin and sectioned at
4mm, and their O6MeG adduct load was quantified using an
anti-O6MeG antibody (Squarix Biotechnology); this antibody
is listed as being specific for human tissue. Antigen retrieval
(10 mM-citrate buffer) was performed, followed by RNase
treatment (20ml RNase A (10 mg/ml), Thermo Fisher Scientific;
5ml RNase T (10 units/ml), Thermo Fisher; 100ml PBS (pH 7·4)
and stopped with a 5 min treatment with NaCl solution
(140 mM)). DNA unwinding was achieved using alkali treat-
ment (70 mM-NaOH/140 mM-NaCl, 1·5 ml) before applying
Special Block A (Covance Laboratories) for 30 min. The
O6MeG antibody (1:1000) was applied to the slides overnight
at room temperature, followed by Special Block B (Covance
Laboratories), before applying poly-horseradish peroxidase
(HRP) anti-mouse IgG. Sections were counterstained with
haematoxylin, and chromogen 3,30-diaminobenzidine tetra-
hydrochloride (DAB) was used to visualise positive O6MeG
staining. All slides were independently and randomly coded
before quantification of nuclear staining for O6MeG with a
computer image analysis protocol(8). Overall, twenty appro-
priate crypts were visualised using an Olympus Micropubl-
isher 3.3 RTV camera and Olysia Bio-report software
(Olympus). Camera and microscope settings were calibrated
before each image to ensure analytical consistency. To identify
a linear path through a single row of nuclei along the crypt
axis for all images taken, image analysis software developed
by the CSIRO Mathematics Informatics and Statistics division,
R. K. L. Leu et al.222
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‘Imview’ and ‘R for Windows’ 2.1.0, was used. Raw colour
(red, green and blue), luminescence (L), normalised colour
values (r ¼ 14 red/L, g ¼ 14 green/L and b ¼ 14 blue/L) and
colour ratio (RoB ¼ 14 r/b) data points were calculated for
each pixel along the length of the linear path. The number
of cells within each half crypt was counted, and the calculated
RoB ratio was then averaged for each nucleus within individ-
ual crypts. Total O6MeG values/crypt were achieved by sum-
mation of the ratio value for each nucleus along the crypt
axis. Representative sections of one individual from each treat-
ment group showing the immunohistochemical staining are
shown in Fig. 2. Proliferation status of cells in the rectal
crypts was determined by standard immunohistochemical
techniques using the proliferating cell nuclear antigen
(PCNA) antibody (PC10), as reported previously(34,35). Slides
were visualised by brown nuclear staining, and assessed as
the number of Ki-67-positive cells/crypt.
Molecular microbiology
Extraction of DNA from stool samples and subsequent quanti-
tative real-time PCR (qPCR) was performed and analysed
according to the method used by Christophersen and col-
leagues(36). In brief, DNA was extracted using a repeat bead
beating and column clean-up method, and qPCR assays
amplified the 16S ribosomal RNA (rRNA) gene (or in the
case of sulphate-reducing bacteria the adenosine-50-phospho-
sulfate reductase (aps) gene) using primers that targeted
bacterial species or groups of interest. The primer pairs and
their amplification conditions are listed in online Supplemen-
tary Table S5. Data are expressed as absolute abundances and
as a proportion of total bacteria. Bacterial targets were chosen
for their relevance to gut health. In other words, we selected
key species (e.g. F. prausnitzii) or groups of bacteria (e.g.
C. coccoides group) that were responsible for the production
of butyrate following fermentation of complex carbohydrates,
particularly RS, by bacteria such Ruminococcus bromii. P. dis-
tasonis was chosen because of its potential role in the clea-
vage of butyrate from the butyrylated RS used in the study.
We also examined changes in some potentially enteropatho-
genic species (e.g. E. coli), as well as in general groups such
as Lactobacillus and Bifidobacterium that are regarded as mar-
kers of bowel health by many. A range of other bacteria such
as those implicated in gut mucus barrier turnover and inflam-
matory bowel disease, such as A. muciniphila, were also tar-
geted. Sulphate-reducing bacteria were included to determine
whether the production of toxic hydrogen sulphide could
contribute to large-bowel DNA adduct formation in response
to red meat treatment.
Statistical methods
All statistical analyses were performed with scripts in R,
version 3.0.1, using the R statistical package(37). Analyses were
carried out using a linear mixed-effects model, with subjects
as the random effect, on either base-10 logarithm-transformed
data, where necessary, or on untransformed data for each of
the variables.
Initial analyses were carried out using the two periods of the
trial, including the baseline and washout periods. However,
data analyses of the initial study showed that some of the
response variables had carry-over effects, including the
primary end-point O6MeG, epithelial proliferation, certain
bacterial species but not SCFA (see the online Supplementary
material for a full study dataset). This was indicated by a sig-
nificant difference between the baseline level and the washout
level of the response variable or a significant interaction
between the week of diet consumption and the response vari-
able. Therefore, the data analyses used in the present study
were only those of the first period of the study (i.e. only
measurement weeks 0 and 4). As a result, the analysis
reported herein was carried out using only the baseline and
the first-period data. The comparison between the groups in
the first period of the trial was carried out using a linear
mixed-effects model, testing for changes from the baseline and
a difference between the treatments. For Tables 1–4, dietary
intake, stool biochemistry, bacterial abundance (percentage
of total bacteria) and rectal biology data for the first period
of the trial are expressed as means with their standard errors
of the mean for both groups (HRM and HRM þ HAMSB),
together with the increment and percentage change for each
group. For each of these means, the significance of the
change from the baseline is indicated. The final column of
each table gives the P value for the difference between the
two treatments at week 4, and these were tested using either
the original data or the log 10-transformed data as appropriate.
The effects on the overall composition of the gut microbiota
were analysed by combining all qPCR assays and performing a
permutational-based multivariate analysis. Data were log-
transformed before producing a resemblance matrix using
Euclidean distance. Differences between the interventions
were tested on first-period cross-sectional comparison only
using Permanovaþ version 1.06 (PRIMER-E). A P value
,0·05 was considered significant.
(a) (b)
(c) (d)
Fig. 2. Light microscope images (20£ optical zoom) of human rectal crypts
showing O6-methyl-2-deoxyguanosine staining intensity from the baseline
and after the 4-week intervention phase selected from participant #20.
Images showing the sections (a) at the end of the high red meat (HRM)
baseline, (b) at the end of the 4-week HRM treatment, (c) at the end of the
HRM þ butyrylated high-amylose maize starch (HAMSB) baseline and (d) at
the end of the 4-week HRM þ HAMSB treatment.
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Results
Study comparisons for the whole dataset
Initial analyses were carried out using the two periods of the
trial, including baseline and washout periods. However, data
analyses of the initial study showed that some of the response
variables had carry-over effects, including the primary end-
point O6MeG, epithelial proliferation, certain bacterial species
but not SCFA (see online Supplementary material for a full
study dataset). There was a significant increase in the rectal
crypt O6MeG adduct load when the participants consumed
the HRM diet first compared with all the other intervention
stages (P,0·01; see online Supplementary Fig. S2(A)); how-
ever, when the participants consumed the HRM þ HAMSB
diet as the first intervention, there was no change in the
O6MeG adduct load with the subsequent consumption of
HRM (see online Supplementary Fig. S2(B)). There was a
significant effect of treatment and treatment order on PCNA-
positive cells/crypt (see online Supplementary Fig. S3(A) and
(B)). For the participants on the HRM or HRM þ HAMSB
diet as their first intervention, the PCNA-positive cells signifi-
cantly increased (P,0·001). For those on the HRM or HRM þ
HAMSB diet (received as their first intervention), the positive
cells significantly decreased after consuming their final
treatment compared with the first treatment. Participants
who consumed the HRM diet as the first treatment had signifi-
cantly higher PCNA-positive cells/crypt compared with those
who consumed the HRM diet as the second treatment
(P,0·001). We also observed that numbers of some bacteria
in the washout phase were significantly different from those
during the entry period or the dietary interventions (see
online Supplementary Tables S3 and S4). The analysis
Table 1. Dietary intake of the study participants during each diet period, based on 3 d weighed food records
(Mean values with their standard errors; percentages)
HRM group (n 10) HRM þ HAMSB group (n 13)†
Baseline Week 4 Baseline Week 4
Mean SEM Mean SEM Increment
Change
(%) Mean SEM Mean SEM Increment
Change
(%) P‡
Energy (kJ/d) 9169 718 9463 613 þ294 3 8578 421 9250 553 þ672 7 0·98
Protein (g/d) 101 11 124* 5 þ23 19 88 4 119** 7 þ31 26 0·81
Fat (g/d) 80 10 77 9 –3 4 67 4 70 8 þ3 4 0·80
Saturated fat (g/d) 31 5 34 4 þ3 9 24 2 30 3 þ6 20 0·75
Carbohydrate (g/d) 221 28 222 20 þ1 1 244 17 256 16 þ12 5 0·36
Sugar (g/d) 112 16 121 10 þ9 7 120 12 129 9 þ9 7 0·78
Starch (g/d) 108 16 99 17 –9 –9 122 9 125 9 þ3 2 0·21
Fibre (g/d) 24 2 19** 2 –5 –26 28 3 29 3 þ1 3 0·01§
Alcohol (g/d) 21 6 22 8 þ1 5 11 2 7 2 –4 –57 0·52
Total Fe (mg/d) 13·6 0·8 15·1 0·8 þ1·5 10 14·4 1·2 16·4 1·5 þ2 12 0·69
Fe from meat (mg/d) 3·7 0·6 7·2*** 0·9 þ3·5 49 2·6 0·5 6·7*** 0·4 4·1 61 0·56
Fe from non-meat (mg/d) 9·9 0·6 7·9 0·8 –2 –25 11·7 1·3 9·7 1·6 –2·0 21 0·92
HRM, high red meat; HAMSB, butyrylated high-amylose maize starch.
Mean value was significantly different from that at baseline: *P,0·05, **P,0·01, ***P,0·001 (linear mixed-effects model).
† HAMSB supplement contains 88 % total carbohydrate, approximately 20 % dietary fibre, 10 % moisture, ,1 % total fat and ,0·75 % protein.
‡P value was obtained for treatment difference at week 4 (linear mixed-effects model).
§P,0·05.
Table 2. Effect of the dietary interventions in the first period on rectal biology
(Mean values with their standard errors; percentages)
HRM group (n 10) HRM þ HAMSB group (n 13)
Baseline Week 4 Baseline Week 4
Mean SEM Mean SEM Increment Change (%) Mean SEM Mean SEM Increment Change (%) P†
O6MeG load
(staining
intensity)
60·8 2·3 77·4** 5·8 16·6 21·4 59·8 3·2 67·5 2·3 7·7 11·4 0·14
PCNA
(positive
cells/crypt)
6·2 0·3 9·9*** 1·0 þ3·8 38 6·6 0·3 8·6* 0·7 þ2·0 23 0·05‡
HRM, high red meat; HAMSB, butyrylated high-amylose maize starch; O6MeG, O6-methyl-2-deoxyguanosine; PCNA, proliferating cell nuclear antigen.
Mean value was significantly different from that at baseline: *P,0·05, **P,0·01, ***P,0·001 (linear mixed-effects model).
†P value was obtained for treatment difference at week 4 (linear mixed-effects model).
‡P,0·05.
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revealed a diet-order effect on the microbiota composition.
When the volunteers consumed the HRM þ HAMSB diet as
the first intervention, their microbiota composition signifi-
cantly differed from that of the entry levels (P¼0·02), as
well as from that of the subsequent HRM intervention
(P¼0·02) and the washout levels (P¼0·005) in the same
volunteers. Furthermore, the microbiota composition of
these volunteers consuming the HRM þ HAMSB diet first
was also significantly different from that of those consuming
HRM first (P¼0·01). However, when the volunteers consumed
the HRM diet first, the microbial composition during the
subsequent consumption of the HRM þ HAMSB diet was
only different from that of the washout levels (P¼0·02).
Study comparisons for the first period
The results arising from the respective baseline periods and
the first arm of the dietary intervention (i.e. at week 4 of the
intervention) are described in detail below, as the results of
the second arm (cross-over) showed carry-over effects for
O6MeG, epithelial proliferation and certain bacterial species.
The study was still adequately powered based on the primary
end-point ‘O6MeG’. Calculations using a two-tailed t test with
a power of 80 % with means of 60·8 and 77·4 and a standard
deviation of 15 showed that group sizes of five were adequate
to detect a difference between the baseline and the HRM
intervention.
Demographic data, participant characteristics and
dietary intake
Recruitment commenced in July 2009, with each participant
followed up for the 4-month duration of the interventions.
Data collection was completed by September 2010. A total
of twenty-five participants were assigned randomly, with
twelve allocated to the HRM dietary intervention first and thir-
teen allocated to the HRM þ HAMSB dietary intervention first.
However, two participants withdrew before the commence-
ment of the intervention diets; one due to unrelated medical
problems and the other due to intolerance of the first rectal
biopsy. Approximately one-third of the participants on the
trial diets reported increased flatulence. Of the volunteers,
ten (seven males and three females; mean age 62·1 (SEM 1·8)
years and mean body weight 79·8 (SEM 5·6) kg) completed
the HRM intervention as the first diet period, while thirteen
(ten males and three females; age 62·7 (SEM 1·7) years and
body weight 82·4 (SEM 3·5) kg) completed the HRM þ HAMSB
intervention first.
Participants maintained consistent body weight, with mean
weights of 77·1 (SEM 6·4) and 82·8 (SEM 3·3) kg after the HRM
and HRM þ HAMSB interventions, respectively.
There was no difference between the diets for reported
intake of energy, total and saturated fat, total carbohydrates
and sugar, starch, alcohol or total Fe intake (Table 1). Com-
pared with their respective baseline levels, protein intake
was significantly increased by the HRM (P,0·05) and HRM þ
HAMSB (P,0·01) interventions. Fibre intake was decreased in
the HRM group at week 4 compared with its baseline levelT
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Table 4. Abundances of species and groups of bacteria (per g of stool and as a percentage of total bacteria)†
(Mean values with their standard errors; percentages)
HRM group (n 10) HRM þ HAMSB group (n 13)
Baseline Week 4 Baseline Week 4
Mean SEM Mean SEM Increment Change (%) Mean SEM Mean SEM Increment Change (%) P‡
Per g of stool
Total bacteria 3·8 £109 7·5 £ 108 4·7 £ 109 6·9 £ 108 þ0·9 £ 109 19 4·0 £ 109 6·5 £ 108 5·4 £ 109 7·3 £ 108 þ1·4 £ 109 26 0·56
Clostridium
coccoides group
5·5 £ 108 1·2 £ 108 6·6 £ 108 8·5 £ 107 þ1·1 £ 108 17 5·9 £ 108 0·9 £ 108 8·2 £ 108* 8·3 £ 107 þ2·2 £ 108 28 0·33
Clostridium
leptum group
5·3 £ 108 1·1 £ 108 7·5 £ 108 1·5 £ 108 þ2·2 £ 108 29 5·1 £ 108 0·9 £ 108 9·2 £ 108* 1·6 £ 108 þ4·1 £ 108 45 0·54
Lactobacillus spp. 3·7 £ 105 1·3 £ 105 5·1 £ 105 1·0 £ 105 þ1·4 £ 105 28 4·7 £ 106 3·6 £ 106 5·8 £ 106** 2·6 £ 106 þ1·1 £ 106 19 0·26
Parabacteroides
distasonis
1·4 £ 107 8·1 £ 106 1·2 £ 107 6·4 £ 106 –2·0 £ 106 17 9·0 £ 106 3·3 £ 106 2·4 £ 108*** 7·9 £ 107 þ2·3 £ 108 96 0·0004§§§
Ruminococcus
bromii
9·0 £ 106 3·1 £ 106 9·7 £ 106 4·6 £ 106 þ0·7 £ 106 7 1·8 £ 107 9·5 £ 106 3·6 £ 107* 1·0 £ 107 þ1·8 £ 107 50 0·02§
Ruminococcus
torques
2·2 £ 107 7·7 £ 106 2·1 £ 107 6·4 £ 106 –1·0 £ 106 5 2·2 £ 107 1·1 £ 107 0·52 £ 107* 0·25 £ 107 –1·7 £ 107 323 0·03§
Percentage of
total bacteria
Escherichia coli 1·08 0·82 1·5 1·04 þ0·4 28 3·39 2·77 2·54** 2·35 –0·9 –34 0·02§
P. distasonis 0·27 0·16 0·2 0·11 –0·1 –35 0·34 0·18 4·37*** 1·6 þ4·0 92·2 0·0001§§§
Ruminococcus
gnavus
0·3 0·12 0·31 0·14 0 0 0·45 0·14 0·22** 0·1 –0·2 –105 0·11
R. torques 1·11 0·55 0·72 0·36 –0·4 –54 0·98 0·58 0·15** 0·09 –0·8 –553 0·03§
HRM, high red meat; HAMSB, butyrylated high-amylose maize starch.
Mean value was significantly different from that at baseline: *P,0·05, **P,0·01, ***P,0·001 (linear mixed-effects model).
† As enumerated using quantitative real-time PCR and showing significant changes in response to the dietary treatments.
‡P value was obtained for treatment difference at week 4 (linear mixed-effects model).
§P,0·05, §§P,0·01, §§§P,0·001.
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(P,0·01). Fibre intake was significantly lower in the HRM
group than in the HRM þ HAMSB group after 4 weeks
(P,0·01). Fe intake from meat was significantly higher for
the HRM and HRM þ HAMSB interventions at week 4 com-
pared with their respective baseline levels (P,0·001).
Rectal epithelial measures
The O6MeG adduct load was increased at week 4 in the HRM
group compared with its baseline level (P,0·01); however,
the addition of HAMSB to the HRM diet prevented this
increase (Table 2). Relative to their respective baseline
levels, the number of PCNA-labelled cells in the rectal epi-
thelium increased for both the HRM (P,0·001) and HRM þ
HAMSB (P,0·05) groups; however, the number was lower
following the HRM þ HAMSB intervention than the HRM
intervention (P,0·05; Table 2).
Stool biochemistry
The results of the stool analyses are presented in Table 3. Stool
output and pH did not differ significantly between the treat-
ments. Stool excretion of acetate, propionate, butyrate and
total SCFA was higher in the HRM þ HAMSB group at 4
weeks compared with its baseline level (P,0·05) as was the
stool concentrations of acetate, propionate and total SCFA
(P,0·05). Faecal p-cresol concentration was lower in the
HRM þ HAMSB group at 4 weeks compared with its baseline
level (P,0·01) and the HRM group (P,0·05). Branched-chain
fatty acids, phenols, NH3 and NOC were unaffected by the
treatment.
Stool bacteria
Significant changes in stool bacteria in response to the diet are
presented in Table 4. When the numbers of bacteria/g of stool
were examined, the HRM þ HAMSB group at 4 weeks elicited
an increase in the number of Parabacteroides distasonis rela-
tive to its baseline level (P,0·0001) and the HRM group
(P,0·001). Compared with its baseline level, HRM þ HAMSB
consumption increased the numbers of Lactobacillus spp.
(P,0·01), the Clostridium coccoides group (P,0·05), the Clos-
tridium leptum group (P,0·05) and Ruminococcus bromii
(P,0·05), but lowered the numbers of Ruminococcus torques
(P,0·05). When bacterial numbers were expressed as a per-
centage of total bacteria, the proportion of P. distasonis was
increased by the consumption of the HRM þ HAMSB diet at
4 weeks compared with its baseline level and the HRM
group at 4 weeks (both P,0·0001). Lower proportions of
Ruminococcus gnavus (P,0·01), R. torques (P,0·01) and
E. coli (P,0·01) were evident in the HRM þ HAMSB group at
4 weeks compared with its baseline level. The HRM þ HAMSB
group also had lower proportions of R. torques (P,0·05) and
E. coli (P,0·05) than the HRM group at 4 weeks. When the
results of all qPCR assays were combined and then analysed
statistically to gain an indication of the impacts of the treat-
ments on microbial diversity, it was found that the microbial
diversity during the HRM þ HAMSB intervention was different
from that at baseline (P,0·05) and during the HRM interven-
tion (P,0·01); however, the composition at baseline and the
HRM intervention did not differ.
Discussion
Previously, we reported that feeding a diet rich in red meat to
rodents can increase the level of the pro-mutagenic DNA
adduct (O6MeG) in the colon, whereas co-consumption of a
fermentable carbohydrate can reduce this effect(8). We have
now shown that when free-living healthy human subjects con-
sumed their normal habitual diet containing at least an
additional 300 g red meat over a 4-week period, there was
increased formation of the O6MeG adduct in the rectal epi-
thelium. This increase in adduct formation might account, in
part, for the increased risk of CRC associated with consuming
high levels of red meat.
Studies in rodents have shown a positive correlation between
cumulative O6MeG levels and tumour load(38). This association
is also supported, in humans, by the prevalence of higher
O6MeG levels in DNA isolated from the distal region of the
colon, where most sporadic CRC occurs(39). The present study
is the first to report on the effect of feeding a HRM diet to
human subjects on the most predominant alkyl-induced DNA
adduct O6MeG in the rectal epithelial tissue. In a randomised
cross-over study comparing HRM, vegetarian and HRM/high-
fibre diets, an increase in O6-carboxymethylguanine adduct
levels was observed in exfoliated colonic epithelial cells isolated
from the faeces of healthy volunteers consuming a HRM diet(7).
However, the relevance of DNA adducts in exfoliated cells to the
in situ epithelial adduct load is unclear. Our findings show that
such adducts do form in cells residing within the crypt and,
thus, have the potential to form mutated clones that might
progress to cancer.
The present study also confirms that dietary fermentable
carbohydrate in the form of HAMSB can protect against
red meat-induced colorectal DNA lesions in humans, and is
consistent with epidemiological evidence that dietary fibre
consumption reduces the risk of CRC. The present study and
our previous work in rodents(8,18,21,40) all point towards SCFA,
particularly butyrate, to be the key mediators in preventing
meat-induced DNA adducts and DNA strand breaks in colonic
mucosa. Butyrate is a preferred metabolic substrate for colono-
cytes, and this SCFA has strong anti-tumorigenic properties
in vivo and in vitro (15,41). In the present study, ingestion of
HAMSB in conjunction with HRM was also able to favourably
influence the colonic luminal environment, as evidenced by
increased levels of SCFA and a reduction in the potentially
toxic protein fermentation product p-cresol. This elevation of
faecal butyrate with HAMSB confirms previous studies in
human subjects(20,42), and has the potential to improve colonic
health and offer protection against CRC. Although consumption
of a blend of types 2 and 3 RS in a recent human trial of heredi-
tary CRC failed to reduce tumour incidence(43), the relatively
low daily intake of RS used in that study may have been insuffi-
cient to increase SCFA levels in stool (which were not
measured). At least 20 g of RS/d may be needed to increase
stool levels of SCFA(44,45).
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A reasonable explanation for the increase in O6MeG
adducts with the HRM intervention is dietary haem. Haem is
abundant in red meat, the majority of which derived from
the diet passes into the large bowel(46). We recently identified
dietary haem as an agent that can increase O6MeG adducts in
the colon of mice(35). Haem Fe-rich meat has also been shown
to increase alkylated DNA adducts in an in vitro digestion
system(47). Dietary haem may also increase the production of
reactive oxygen species, causing cellular toxicity and pro-
mutagenic lesions(48,49). Other factors, such as bile acids(50),
could also contribute to adduct formation and DNA damage
more broadly. Haem may also be responsible for the increased
rectal cell proliferation in response to HRM and HRM þ
HAMSB consumption, as evidenced by more PCNA-labelled
cells/crypt. Haem is associated with increased epithelial pro-
liferation in the colon of rodents, and can injure the colonic
surface epithelium by generating cytotoxic and oxidative
stress(6,51).
In the present study, we anticipated that NOC would
increase in the stool of the participants consuming the HRM
diet, and that this would explain a higher O6MeG adduct
load. High dietary haem and red meat have previously been
associated with increased luminal NOC in humans(24,27,52). A
dose–response relationship has been described between red
meat intake and faecal NOC: low faecal NOC (374mg/kg) at
low red meat intake (60 g/d) and a 4- or 5-fold increase in
faecal NOC with increased red meat intake of 240 and
420 g/d, respectively(24). Lewin et al.(7) also observed an
increase in faecal NOC in volunteers fed 420 g/d of red meat
in comparison with a vegetarian diet, and suggested that
NOC are important genotoxins involved in the generation of
alkyl adducts(7). Although we observed an increase in the
O6MeG adduct load with HRM intake (300 g/d), we are
unable to completely explain the lack of the effect of HRM on
faecal NOC. One possible explanation is that the other
studies(7,24) had a very high level of control with the meals
being consumed in an experimental facility. In the present
study, we only controlled for the amount of meat in the diet
so that other factors in the diet may account for the discrepancy.
There is growing recognition of both the importance of the
large-bowel microbiota in human health and the strong role of
diet in modulating its composition and metabolic activities.
Using a suite of qPCR assays that targeted a range of bacteria
important to gut health, we demonstrated significant shifts in
the composition of the gut microbiota in response to the
HRM þ HAMSB, but not HRM, intervention. Our observation
of an increase in the stool numbers of the C. leptum group
and R. bromii, a member of the C. leptum group, in response
to the consumption of RS as HAMSB is consistent with the
effects previously observed in human subjects and with the
central role that this bacterium appears to have in RS degra-
dation(53–55). This increase provides further evidence
(additional to the observed increase in stool SCFA levels)
that HAMSB was being consumed by the participants and
was reaching the large bowel where it was available for fer-
mentation. The numbers of P. distasonis were also increased
by the HAMSB treatment, which is also consistent with
changes in humans following consumption of butyrylated
RS(20). HAMSB is a chemically modified RS, and the forms of
RS (classified as RS4) have been shown to be more likely to
stimulate the growth of P. distasonis (53). In line with the
HAMSB treatment, stool excretion of butyrate increased, pri-
marily from the release of the bound butyrate; however, the
higher number of bacteria in the C. coccoides group could
also have contributed as a number of butyrate producers are
classified in that group.
When the numbers of bacteria were expressed as a pro-
portion of total bacteria, the addition of HAMSB to the
diet also lowered the numbers of E. coli (a species with enter-
opathogenic variants and potential), R. gnavus and R. torques
(numbers of which are high in the mucosa of some individuals
with inflammatory bowel disease)(56), supporting the potential
of HAMSB to promote gut health. We did not observe any
clear indication of the effects of HRM on the composition of
the gut microbiota. However, the range of bacteria that we tar-
geted is limited, and a more detailed analysis of populations
may reveal changes. This may give an insight into the mech-
anisms of HRM-induced adduct formation and reasons for
the associated increased risk of CRC. Furthermore, in vitro
experiments have demonstrated that the formation of
alkylated DNA adducts appear to depend on the microbial
composition(47). The changes that we have observed support
the idea that the increases in stool SCFA levels and the associ-
ated protection against dietary HRM-mediated colorectal tissue
damage that have occurred in response to dietary RS treatment
are at least partly mediated by the gut microbiota, through
both cleavage of the esterified butyrate and fermentation of
the RS substrate. Part of the protective effect may also be
attributable to reducing numbers and activities of bacteria
with potential for harm.
A limitation of the present study was that the randomised
cross-over design resulted in a period effect for the primary
end-point ‘O6MeG adducts’. Participants allocated the HRM þ
HAMSB intervention in the first period did not have a HRM-
induced increase in O6MeG adducts during the subsequent
period. This contrasted with the increase in adduct formation
that occurred when HRM was consumed first. This suggests
that the consumption of HAMSB is able to protect against
the damage caused by the HRM diet. We have presented in
detail the analyses of the data from the first period (results
incorporating both treatment periods are supplied in the
online Supplementary material). Presentation of the data
from the first arm reduces the statistical power of the study
compared with that of the full cross-over. However, the pri-
mary end-point ‘O6MeG’ was still adequately powered, and
the effect of HAMSB on SCFA (especially butyrate) is magni-
fied. A further limitation of the study was that the right-sided
colonic mucosa could not be evaluated, as biopsies were
only taken from the rectum. This limits the application of
the results to proximal colorectal carcinogenesis, particularly
as genotypic differences between proximal and distal cancers
exist(57). More invasive studies are warranted to investigate
whether the same effects observed in the rectum occur in
other regions of the large bowel.
In summary, our findings show that high dietary red meat
intake has detrimental effects on the colorectum by increasing
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pro-mutagenic DNA adducts and epithelial cell proliferation.
Conversely, increasing luminal butyrate levels with HAMSB
prevented the accumulation of O6MeG adducts. These find-
ings might explain the increased risk for CRC associated
with HRM consumption, and could point to a beneficial
effect of butyrate-generating RS.
Supplementary material
To view supplementary material for this article, please visit
http://dx.doi.org/10.1017/S0007114515001750
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